跳至主要内容
临床试验/NCT02806869
NCT02806869已完成不适用

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment: A Research Study to Evaluate the Performance of an Ibuprofen Oral Dosage Form in the Gastrointestinal Tract of Healthy Adult Volunteers

University of Michigan1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
48
试验地点
1
主要终点
Average Duodenal Fluid pH in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen

研究概览

简要总结

In vivo drug dissolution in the gastrointestinal (GI) tract is largely unmeasured. The purpose of this clinical study was to evaluate the in vivo drug dissolution and systemic absorption of the BCS Class IIa drug ibuprofen under fed and fasted conditions by direct sampling of stomach and small intestinal luminal content. Expanding current knowledge of drug dissolution in vivo will help to establish physiologically relevant in vitro models predictive of drug dissolution.

详细描述

This is an in vivo study designed to acquire human gastrointestinal (GI) physiology data from healthy subjects under fasting and fed conditions which are necessary for mechanistic absorption model development. Each subject will be asked to complete two GI tube insertion procedures. Subjects will complete this study twice under the same conditions of the GI tract, either fasting state or fed state, in order to provide intra-subject variability. A minimum of 7 days will separate each GI tube insertion procedure. The objectives of this study are, as follows: Objective #1: To acquire human GI physiology data including GI motility, pH of GI fluids, and GI fluid volume under fasting and fed conditions; Objective #2: To measure drug concentration and calculate drug dissolution in the GI tract in vivo under fasting and fed conditions; Objective #3: To monitor plasma drug concentration and evaluate pharmacokinetics of administered drug during GI tube insertion studies under fasting and fed conditions. These in vivo results will be used to validate in vitro dissolution methods and to support computational and mathematical modeling efforts, in order to develop an oral drug product optimization process that may be applied to future drugs to maximize oral drug safety and efficacy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Adults age 18 to
  • Male or female voluntarily able to give informed consent.

排除标准

  • Adults unable to consent for themselves or mentally incapacitated.
  • Significant clinical illness within 3 weeks prior to Screening.
  • Use of concomitant medications within 2 weeks prior to receiving study drug, including but not limited to prescription drugs, herbal and dietary supplements, over the counter medications, and vitamins. Birth control is permitted.
  • Received an investigational drug within 60 days prior to receiving the study drug.
  • History of gastrointestinal surgery.
  • Surgery within the past 3 months.
  • History of allergy to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs).
  • History of severe allergic diseases including drug allergies, with the exception of seasonal allergies.
  • Any other factor, condition, or disease, including, but not limited to, cardiovascular, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the patient or impact the validity of the study results.
  • History of drug addiction or alcohol abuse within the past 12 months.
  • Pregnant or lactating females.
  • Any clinically significant abnormal lab values during Screening.

研究组 & 干预措施

Arm #2 - Fed State, 2 study visits

Experimental
  1. Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
  2. Washout period of at least 7 days
  3. Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red

干预措施: Pulmocare, two 8.0 oz (236.6 mL) cans (Dietary Supplement)

Arm #1 - Fasting State, 2 study visits

Experimental
  1. Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
  2. Washout period of at least 7 days
  3. Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red

干预措施: Single dose of ibuprofen (800 mg tablet) (Drug)

Arm #2 - Fed State, 2 study visits

Experimental
  1. Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red
  2. Washout period of at least 7 days
  3. Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red

干预措施: Single dose of ibuprofen (800 mg tablet) (Drug)

结局指标

主要结局

Average Duodenal Fluid pH in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen

时间窗: from time 0 to 7 hours

The pH of duodenal fluid was measured at multiple timepoints over a 7 hour period. The reported value represents the mean and standard deviation of duodenal fluid pH.

次要结局

  • Maximum Duodenal Fluid Concentration of Ibuprofen in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen(from time 0 to 7 hours)
  • Average Area Under the Plasma Concentration-time Curve (AUC) in Fasted Compared to Fed Participants Administered a Single Dose of Ibuprofen(from time 0 to 24 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Duxin Sun

Professor

University of Michigan

研究点 (1)

Loading locations...

相似试验